ID   KS24.22
AC   CVCL_E6X8
RX   PubMed=11358828;
RX   PubMed=15365776;
WW   Info; ClinicalTrials.gov; NCT01127074; https://clinicaltrials.gov/study/NCT01127074
CC   HLA typing: A*02:01 (PubMed=11358828).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:1700; CD80.
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:3430; ERBB2.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E6X7 ! KS24
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=11358828;
RA   Pascolo S., Schirle M., Guckel B., Dumrese T., Stumm S., Kayser S.,
RA   Moris A., Wallwiener D., Rammensee H.-G., Stevanovic S.;
RT   "A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.";
RL   Cancer Res. 61:4072-4077(2001).
//
RX   PubMed=15365776; DOI=10.1007/s00262-004-0583-z; PMCID=PMC11034349;
RA   Guckel B., Stumm S., Rentzsch C., Marme A., Mannhardt G.,
RA   Wallwiener D.;
RT   "A CD80-transfected human breast cancer cell variant induces
RT   HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as
RT   well as in vivo.";
RL   Cancer Immunol. Immunother. 54:129-140(2005).
//